Uni-Bio Science Group Limited Uni-Bio Science Group Limited

Uni-Bio Science Group Limited

0690

Rank in Stocks #22824
Uni-Bio Science Group Limited functions as an investment holding enterprise... Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Share Price
$0.00803081
Last synced: 2026-11-13
Market Cap
$47.95M
Change (1 day)
-1.56%
Change (1 year)
-46.57%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Uni-Bio Science Group Limited (0690)

Category

Healthcare
Operating Margin for Uni-Bio Science Group Limited (0690)
Operating Margin as of November 2026 TTM: -8.38%
According to Uni-Bio Science Group Limited's latest financial reports, its current operating margin (TTM) is -8.38%. At the end of 2025 the company had an operating margin of 15.35%.
Operating Margin history for Uni-Bio Science Group Limited from 2002 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -8.38% -154.59%
2025 15.35% -5.54%
2024 16.25% 16.24%
2023 13.98% 61.81%
2022 8.64% -550.00%
2021 -1.92% -92.53%
2020 -25.72% 352.82%
2019 -5.68% -93.52%
2018 -87.69% 85.90%
2017 -47.17% 29.52%
2016 -36.42% -25.75%
2015 -49.05% -5.02%
2014 -51.64% -28.75%
2013 -72.48% -43.43%
2012 -128.12% 38.58%
2011 -92.45% -22.86%
2010 -119.85% 478.99%
2009 -20.70% -153.57%
2008 38.64% 4.91%
2007 36.83% -181.43%
2006 -45.23% -1,280.94%
2005 3.83% -165.25%
2004 -5.87% 1,530.56%
2003 -0.36% -101.74%
2002 20.65% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -76.68%
US
33.87% -104.04%
US
-116.04% -86.15%
US
25.57% -103.05%
AU
31.23% -103.73%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Uni-Bio Science Group Limited's operating margin

What is Uni-Bio Science Group Limited's operating margin?

Uni-Bio Science Group Limited's operating margin is -8.38%, as of Nov 2026.

What was Uni-Bio Science Group Limited's operating margin in 2025?

In 2025, Uni-Bio Science Group Limited's operating margin was 15.35%, compared with 16.25% in 2024.

How has Uni-Bio Science Group Limited's operating margin changed since 2020?

From 2020 to 2025, Uni-Bio Science Group Limited's operating margin was highest in 2024 (16.25%) and lowest in 2020 (-25.72%).

How does Uni-Bio Science Group Limited's operating margin compare with similar companies?

Uni-Bio Science Group Limited's operating margin (-8.38%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.